Deletion of IKZF1 (Ikaros) in Acute Lymphoblastic Leukemia (SJ-08-0011)

Technology Name
(St. Jude Reference #)
Deletion of IKZF1 (Ikaros) in Acute Lymphoblastic Leukemia (SJ-08-0011)
Description Investigators at St. Jude Children's Research Hospital have discovered the IKZF1 gene, which encodes the Ikaros transcription factor, is deleted in a majority of  BCR-ABL1 positive acute lymphoblastic leukemia (ALL) cases and is an acquired deletion during transformation of chronic myelogenous leukemia (CML) to ALL (lymphoid blast crisis). BCR–ABL1-positive ALL constitutes approximately 40% of adult ALL and 5% of pediatric B-progenitor ALL. The IKZF1 deletion represents the most frequently associated genetic lesion in any subtype of acute leukemia.

An assay showing a deleted Ikaros protein in CML patients would suggest that monotherapy with ABL kinase inhibitors such as imatinib may be unsuccessful, and more aggressive therapy would be required. Furthermore, recent studies conducted at St. Jude show the Ikaros status is also of key prognostic importance in BCR-ABL1 negative ALL.
Keywords AML and CML cancer diagnostic, Ikaros deletion
Granted Patents or Published Applications US Publication No. 2010/0240057, International application published on May 14 2009 as WO 2009/061890 A1
Related Scientific References Mullighan C., et al., BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros, Nature 2008 May 1;453(7191):110-4
Licensing Opportunities We are currently seeking licensing opportunities in all fields, in particular to develop a diagnostic test for ALL and CML.


Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.


Last update: September 2014